Phase I/II study of Amrubicin with Cisplatin in patients with advanced Non-small cell lung cancer
Not Applicable
- Conditions
- Advanced Non-small cell lung cancer
- Registration Number
- JPRN-jRCT1080221989
- Lead Sponsor
- Dainippon Sumitomo Pharma Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
Patients with advanced non-small cell lung cancer who satisfy the following inclusion criteria
-No prior chemotherapy
-Performance status of 0-1
etc.
Exclusion Criteria
-Prior radiotherapy for primary lesion
-Pneumonitis and/or pulmonary fibrosis
-Active concomitant malignancy
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy<br>Overall response rate
- Secondary Outcome Measures
Name Time Method Efficacy, Safety<br>Overall survival, Adverse Events, Adverse Reactive Reactions